by andrewmm2007 | Nov 5, 2022 | Featured News
Novadip Biosciences, a Belgium-based biopharmaceutical company, has raised an additional €40 million in a Series B equity round and non-dilutive funding.
by andrewmm2007 | Nov 4, 2022 | Featured News
The clinical-stage biopharma company is developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment.
by andrewmm2007 | Nov 4, 2022 | Featured News
Novadip Biosciences, a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has raised an additional EUR 40 million ($39.1 million) in a Series B...
by andrewmm2007 | Nov 3, 2022 | Press Releases
MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a...
by andrewmm2007 | Oct 17, 2022 | Past Events
Innovators & Investors Come Together to Shape the Future of Therapeutics 550+ ATTENDEES INCLUDING BIOPHARMA, LIFE SCIENCE, DIGITAL MEDICINE, INVESTORS
